FDA approves Novartis Afinitor to treat kidney tumors Pharmaceutical Business Review The US Food and Drug Administration (FDA) has approved Novartis Afinitor (everolimus) to treat patients with non-cancerous kidney tumors associated with tuberous sclerosis complex (TSC). The approval was based on the Phase III EXamining everolimus In a ... |
